Maintaining and optimising anti-TNF therapy.
作者信息
Somerville Margaret
机构信息
Rheumatology Unit, Norfolk & Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK.
出版信息
Musculoskeletal Care. 2007 Dec;5 Suppl 1:1-17. doi: 10.1002/msc.123.
DOI:10.1002/msc.123
PMID:18050263
Abstract
摘要
相似文献
1
Maintaining and optimising anti-TNF therapy.维持和优化抗TNF治疗。
Musculoskeletal Care. 2007 Dec;5 Suppl 1:1-17. doi: 10.1002/msc.123.
2
3
Anti-tumour necrosis factor therapy in the West Midlands.西米德兰兹郡的抗肿瘤坏死因子治疗
Rheumatology (Oxford). 2004 Mar;43(3):400; author reply 400-1. doi: 10.1093/rheumatology/keh042.
4
[TNF antagonists in therapy of rheumatoid arthritis].[肿瘤坏死因子拮抗剂在类风湿关节炎治疗中的应用]
Med Monatsschr Pharm. 1999 Nov;22(11):334-9.
5
Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.利妥昔单抗与抗肿瘤坏死因子-α阻滞剂联合治疗成功治愈严重难治性类风湿关节炎。
J Rheumatol. 2009 Sep;36(9):2125-6. doi: 10.3899/jrheum.090160.
6
Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.医疗保险对肿瘤坏死因子α抑制剂的覆盖范围对医生处方行为的影响。
Arch Intern Med. 2006 Jan 9;166(1):57-63. doi: 10.1001/archinte.166.1.57.
7
Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.不同疾病严重程度和活动度的类风湿关节炎患者中医生的治疗偏好：成本对一线治疗的影响。
Arthritis Rheum. 2002 Jun 15;47(3):285-90. doi: 10.1002/art.10456.
8
Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.770例风湿性疾病患者在日常临床实践中肿瘤坏死因子阻滞剂的留存率。
J Rheumatol. 2006 Dec;33(12):2433-8. Epub 2006 Oct 1.
9
[Anti-rheumatoid biologics and pharmacoeconomic evaluation].[抗类风湿生物制剂与药物经济学评估]
Nihon Rinsho. 2005 Jan;63 Suppl 1:711-8.
10
Biologic therapy for rheumatoid arthritis.类风湿关节炎的生物治疗
N Engl J Med. 2000 Nov 30;343(22):1640-1. doi: 10.1056/NEJM200011303432210.
Zotero 插件